136 related articles for article (PubMed ID: 35575415)
21. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
[TBL] [Abstract][Full Text] [Related]
22. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
23. Early recognition of aggressive pituitary adenomas: a single-centre experience.
Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C
Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844
[TBL] [Abstract][Full Text] [Related]
24. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
25. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
26. Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management.
Zemmoura I; Wierinckx A; Vasiljevic A; Jan M; Trouillas J; François P
Pituitary; 2013 Dec; 16(4):515-22. PubMed ID: 23184261
[TBL] [Abstract][Full Text] [Related]
27. Pituitary carcinoma: a clinicopathologic study of 15 cases.
Pernicone PJ; Scheithauer BW; Sebo TJ; Kovacs KT; Horvath E; Young WF; Lloyd RV; Davis DH; Guthrie BL; Schoene WC
Cancer; 1997 Feb; 79(4):804-12. PubMed ID: 9024719
[TBL] [Abstract][Full Text] [Related]
28. Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature.
Campana C; Nista F; Castelletti L; Caputo M; Lavezzi E; Marzullo P; Ferrero A; Gaggero G; Canevari FR; Rossi DC; Zona G; Lania A; Ferone D; Gatto F
J Endocrinol Invest; 2022 Aug; 45(8):1465-1481. PubMed ID: 35147925
[TBL] [Abstract][Full Text] [Related]
29. Differences between rat strains in the development of PRL-secreting pituitary tumors with long-term estrogen treatment: In vitro insulin-like growth factor-1-induced lactotroph proliferation and gene expression are affected in Wistar-Kyoto rats with low estrogen-susceptibility.
Mitsui T; Ishida M; Izawa M; Arita J
Endocr J; 2013; 60(11):1251-9. PubMed ID: 23985690
[TBL] [Abstract][Full Text] [Related]
30. Mixed Sparsely Granulated Lactotroph and Densely Granulated Somatotroph Pituitary Neuroendocrine Tumor Expands the Spectrum of Neuroendocrine Neoplasms in Ovarian Teratomas: the Role of Pituitary Neuroendocrine Cell Lineage Biomarkers.
Hodgson A; Pakbaz S; Shenouda C; Francis JA; Mete O
Endocr Pathol; 2020 Sep; 31(3):315-319. PubMed ID: 32632841
[No Abstract] [Full Text] [Related]
31. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
[TBL] [Abstract][Full Text] [Related]
32. Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma.
Nasr C; Mason A; Mayberg M; Staugaitis SM; Asa SL
J Clin Endocrinol Metab; 2006 Dec; 91(12):4776-80. PubMed ID: 16968791
[TBL] [Abstract][Full Text] [Related]
33. Estrogen actions on lactotroph proliferation are independent of a paracrine interaction with other pituitary cell types: a study using lactotroph-enriched cells.
Ishida M; Takahashi W; Itoh S; Shimodaira S; Maeda S; Arita J
Endocrinology; 2007 Jul; 148(7):3131-9. PubMed ID: 17412817
[TBL] [Abstract][Full Text] [Related]
34. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
[TBL] [Abstract][Full Text] [Related]
35. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
36. Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.
Kara M; Tokat F; Pamir MN; Danyeli AE
Endocr Pathol; 2020 Jun; 31(2):166-173. PubMed ID: 32157655
[TBL] [Abstract][Full Text] [Related]
37. Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas.
Zhang D; Way JS; Zhang X; Sergey M; Bergsneider M; Wang MB; Yong WH; Heaney AP
J Clin Endocrinol Metab; 2019 Jun; 104(6):1929-1936. PubMed ID: 30624667
[TBL] [Abstract][Full Text] [Related]
38. [Pituitary lactotroph adenomas resistant to dopamine agonist treatment: histological and immunohistochemical characteristics].
Fedorova NS; Abrosimov AY; Dzeranova LK; Pigarova EA; Dedov II
Arkh Patol; 2018; 80(3):34-39. PubMed ID: 29927438
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneity of pituitary lactotrophs: immunocytochemical identification of functional subtypes.
De Paul AL; Pons P; Aoki A; Torres AI
Acta Histochem; 1997 Aug; 99(3):277-89. PubMed ID: 9381911
[TBL] [Abstract][Full Text] [Related]
40. Aggressive prolactinoma (Review).
Valea A; Sandru F; Petca A; Dumitrascu MC; Carsote M; Petca RC; Ghemigian A
Exp Ther Med; 2022 Jan; 23(1):74. PubMed ID: 34934445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
